1. Home
  2. SHAZ vs MLYS Comparison

SHAZ vs MLYS Comparison

Compare SHAZ & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SharonAI Holdings Inc. Class A Common Stock

SHAZ

SharonAI Holdings Inc. Class A Common Stock

N/A

Current Price

$49.96

Market Cap

2.8B

Sector

Technology

ML Signal

N/A

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$23.73

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SHAZ
MLYS
Founded
2024
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.5B
IPO Year
2025
2023

Fundamental Metrics

Financial Performance
Metric
SHAZ
MLYS
Price
$49.96
$23.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
★ $110.00
$48.50
AVG Volume (30 Days)
1.2M
★ 1.2M
Earning Date
11-15-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 37.43
EPS
N/A
★ N/A
Revenue
★ $1,566,631.00
N/A
Revenue This Year
$7,470.09
N/A
Revenue Next Year
$1,195.12
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 257.44
N/A
52 Week Low
$16.55
$22.30
52 Week High
$97.48
$47.65

Technical Indicators

Market Signals
Indicator
SHAZ
MLYS
Relative Strength Index (RSI) 44.25 41.01
Support Level $48.65 $22.36
Resistance Level $62.37 $31.19
Average True Range (ATR) 3.68 1.37
MACD -0.13 -0.43
Stochastic Oscillator 27.65 15.65

Price Performance

Historical Comparison
SHAZ
MLYS

About SHAZ SharonAI Holdings Inc. Class A Common Stock

SharonAI Holdings Inc is a neocloud operator, purpose-built to power the next generation of artificial intelligence (AI) and high-performance computing (HPC). The Company's infrastructure is architected from the ground up to meet the specific, intensive, and complex demands of modern AI training and inference workloads, machine learning, and Generative AI. Its services include: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, and SHARON AI Studio. The company's products are: SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, and Machine Learning & Infrastructure. The Company operates in one operating segment, High Performance Compute Services (HPC).

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: